LIFECORE BIOMEDICAL, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
LIFECORE BIOMEDICAL, INC. (LFCR) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $7.88 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-05
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $7.88.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-09-30 was $8.01.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-08-25 was $5.28, a 49.62% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-08-27 was $10.48.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $6.64, a 13.77% decline from fiscal 2024.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $7.70, a 26.74% decline from fiscal 2023.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $10.51, a 10.86% decline from fiscal 2022.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $11.79, a 22.05% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 7 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $7.88 10-Q · filed 2026-08-05 | ||||
| 2026-03-31 | $7.88 10-Q · filed 2026-05-06 | ||||
| 2025-12-31 | $6.81 10-KT · filed 2026-03-16 | ||||
| 2025-09-30 | $8.01 10-Q · filed 2025-11-06 | ||||
| 2025-05-25 | $6.64 10-K · filed 2025-08-07 | ||||
| 2025-02-23 | $6.83 10-Q · filed 2025-04-03 | ||||
| 2024-11-24 | $5.00 10-Q · filed 2025-01-02 | ||||
| 2024-08-25 | $5.28 10-Q · filed 2024-10-04 | ||||
| 2024-05-26 | $7.70 10-K · filed 2024-08-26 | ||||
| 2024-02-25 | $7.51 10-Q · filed 2024-08-09 | ||||
| 2023-11-26 | $10.48 10-Q · filed 2024-08-09 | ||||
| 2023-08-27 | $10.48 10-Q · filed 2024-08-09 | ||||
| 2023-05-28 | $10.51 10-K · filed 2024-03-20 | ||||
| 2022-05-29 | $11.79 10-K · filed 2024-03-20 | ||||
| 2021-05-30 | $9.66 10-K · filed 2024-03-20 | ||||
| 2020-05-31 | $10.42 10-K/A · filed 2023-03-16 | ||||
| 2019-05-26 | $11.85 10-K · filed 2021-07-29 | ||||
| 2018-05-27 | $12.93 10-K · filed 2020-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |